Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-34 (Canceled).

35. (Currently Amended) A chemical compound of formula (I):



(I)

wherein:

R_1 to R_3 are independently selected from hydrogen and lower alkyl;

X_1 is selected from N and C-R_4;

X_2 is selected from N and C-R_5;

X_3 is selected from N and C-R_6;

X_4 is selected from N and C-R_7;

wherein only one of X_1 to X_4 is N;

R_4, R_5 and R_7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkoyl, aryloyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino, nitro, cyano, carboalkoxy, carboaryloxy and carboxy; and

R_6 is selected from hydrogen, halogen, alkyl, aryl, aryloxy, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino and cyano;

with the proviso that R_4 to R_7 are not all selected as hydrogen,

or a pharmaceutically acceptable salt[[,]] or addition compound ~~or prodrug~~ thereof.

36. (Previously Presented) A compound according to claim 35, wherein R_1 is selected from hydrogen and methyl.

37. (Previously Presented) A compound according to claim 35, wherein R_2 is hydrogen.

38. (Previously Presented) A compound according to claim 35, wherein R_3 is selected from hydrogen and methyl.

39. (Previously Presented) A compound according to claim 35, wherein X_2 is C-R_5.

40. (Previously Presented) A compound according to claim 35, wherein X_3 is C-R_6.

41. (Previously Presented) A compound according to claim 35, wherein X_4 is C-R_7.

42. (Previously Presented) A compound according to claim 35, wherein X_1 is C-R_4.

43. (Previously Presented) A compound according to claim 35, wherein two of R_4, R_5, R_6 and R_7 are hydrogen.

44. (Previously Presented) A compound according to claim 43, wherein R_4 and R_6 are hydrogen.

45. (Previously Presented) A compound according to claim 35, wherein two of R_4, R_5, R_6 and R_7 are independently selected from hydrogen, chlorine, fluorine, trifluoromethyl and bromine.

46. (Previously Presented) A compound according to claim 35, wherein three of R_4, R_5, R_6 and R_7 are hydrogen.

47. (Previously Presented) A compound according to claim 46, wherein R_4, R_6 and R_7 are hydrogen.

48. (Previously Presented) A compound according to claim 35, wherein R_4 is hydrogen.

49. (Previously Presented) A compound according to claim 35, wherein R_5 is halogen.

50. (Previously Presented) A compound according to claim 35, wherein R_6 is hydrogen.

51. (Previously Presented) A compound according to claim 35, wherein R_7 is halogen.

52. (Previously Presented) A compound according to claim 35, wherein the compound is:

(RS) 7-Chloro-1,2,3,4,10,10a-hexahydro-6-aza-pyrazino[1,2-a]indole furmarate.

53. (Previously Presented) A method of treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea comprising administering to a patient in need of such treatment an effective does of a compound of formula (I) as set out in claim 35.

54. (Previously Presented) A method according to claim 53, wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioural disorders, behavioural disorders associated with dementia,

organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

55. (Previously Presented) A method according to claim 53, wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases or toxic or infective CNS diseases.

56. (Previously Presented) A method according to claim 55, wherein said toxic or infective CNS disease is encephalitis or meningitis.

57. (Previously Presented) A method according to claim 53, wherein the cardiovascular disorder is thrombosis.

58. (Previously Presented) A method according to claim 53, wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.

59. (Previously Presented) A method according to claim 53, wherein said disorder is obesity.

60. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) as set out in claim 35 in combination with a pharmaceutically acceptable carrier or excipient.

61. (Previously Presented) A method of making a pharmaceutical composition comprising combining a compound of formula (I) as set out in claim 35 with a pharmaceutically acceptable carrier or excipient.

62. (Previously Presented) A process for the preparation of a compound of formula (I) according to claim 35, said process comprising the steps of:

(i) treating a compound of formula (IX) with an aldehyde of formula RCHO and then exposing the compound to acid to obtain a compound of formula (X), wherein X_1, X_2, X_3, X_4, R_2 and R_3 are as described in claim 35, and



(ii) reduction of a compound of formula (X).